As of February 27, 2023, around 77.5 percent of the population in Japan received the second dose of coronavirus disease (COVID-19) vaccination. At the same time, approximately 68.4 percent of the population had a booster shot.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

As of February 2023, about 95.8 percent of citizens aged 90 to 99 years in Japan received the third dose of coronavirus disease (COVID-19) vaccinations. The overall share of around 68.4 percent of inhabitants in Japan was vaccinated with the third dose as of the same day.

As of March 16, 2022, close to 79 percent of inhabitants in Akita Prefecture received the second dose of coronavirus disease (COVID-19) vaccination, the highest vaccination rate among all 47 prefectures in Japan. In terms of the booster shot, Yamaguchi Prefecture recorded at around 40.6 percent.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

Forecast: Measles Vaccination Rates Among Children in Japan 2022 - 2026 Discover more data with ReportLinker!

This statistic presents the results of a survey on perceived percentage of infants who receive all the WTO recommended vaccinations in Japan as of October 2018. According to data published by Ipsos, Japanese respondents underestimated the coverage of vaccinations of infants in Japan. On average, the respondents thought that around ** out of every 100 Japanese infants under 12 months have had all the recommended vaccines for diphtheria, tetanus, whooping cough, polio, and measles, when the actual infant vaccination coverage was ** percent in Japan.

This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021–2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (n = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; n = 234) and COVID-19 (94.3%; n = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were “managing director’s willingness to recommend” and “pneumococcal vaccination request from the residents.” The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required. Pneumococcal vaccination rates and factors associated with the vaccination of elderly care facility residents are important for policymakers and academia when considering the development and implementation of vaccination programs and guidelines for the management of residents in these facilities. This study evaluated how many elderly people living in care facilities in Japan got pneumococcal vaccine, comparing it with their rates of getting influenza (2021–2022 vaccination only) and COVID-19 vaccines. The information was collected from managing directors of these facilities through an online survey (September 5, 2022-November 25, 2022). Of the 1,313 managing directors contacted, 445 responded. Among the 42 facilities that had recorded pneumococcal vaccination history of their residents, the average vaccination rate was 31.1%, which was much lower than the rates for influenza (93.1%) and COVID-19 (94.3%) vaccines. Only a small percentage of facilities (6.5%) had high (80% to 100%) pneumococcal vaccination rates, while most had high rates for influenza (80.5%) and COVID-19 vaccines (89.6%). Managing directors recommending the pneumococcal vaccine and residents requesting it were major factors in higher vaccination rates. Most managing directors who recommended pneumococcal vaccine believed it was effective, while those who did not recommend often did not understand its effectiveness. In conclusion, there is a need to increase pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as raising awareness among managing directors, encouraging them to recommend the vaccine (especially for residents not covered by national subsidy programs), and providing regular training on the vaccine to staff and residents are required.

Actual value and historical data chart for Japan Immunization Bcg Percent Of One Year Old Children

Even though they are important determinants for increasing vaccination rates in advanced and developing nations alike, maternal capacity and decisional authority have not been fully elucidated in diverse countries and cultural spheres. This study examined the effects of South Korean, Chinese, and Japanese mothers’ health literacy, self-efficacy, mass media use, and decisional authority on their children’s vaccination after adjustment for their socioeconomic statuses. Computer-assisted web interviews were conducted with married women in their 20s-40s of South Korean, Chinese, or Japanese nationality (n = 1,571). Dependent variables were generated for the following four vaccinations: BCG, diphtheria+pertussis+tetanus (DPT), poliomyelitis (polio), and measles. For statistical processing, cases where all four types of vaccines had been recorded were scored as 1 and other cases were processed as 0. According to the results of the pooled model, we found that for East Asian mothers, decisional authority, self-efficacy, and health literacy all increased the likelihood that they would vaccinate their children. Furthermore, women who searched for health information through media such as the radio were more likely to vaccinate their children. However, when elaborate analyses were conducted by country, there were considerable differences in those characteristics by country. Therefore, this study showed that it is necessary to establish locally tailored strategies in order to raise vaccination rates in the Global Vaccine Action Plan. This study also showed that social contexts must be taken into consideration in order to raise vaccination rates.

Forecast: Total Influenza Vaccination Rates in Japan 2022 - 2026 Discover more data with ReportLinker!

The Japan vaccine market was valued at USD 4.15 Billion in 2024, driven by the introduction of innovative vaccine technologies in the region. The market is anticipated to grow at a CAGR of 8.30% during the forecast period of 2025-2034, with the values likely to reach USD 9.21 Billion by 2034. The increasing government initiatives for vaccine development and Japan's strong healthcare infrastructure are likely to enhance widespread vaccination access and drive market expansion.

Immunization, measles (% of children ages 12-23 months) in Japan was reported at 95 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

In 2018, the rate of children vaccinated against diphtheria, tetanus, and pertussis in Japan reached about ** percent, up ***** percentage points from 2015.

Global Japan Conjugate Vaccine Market is segmented by Application (Pneumococcal vaccines_ Meningococcal vaccines_ Hib vaccines_ Hepatitis vaccines_ Pneumococcal vaccines), Type (Vaccine types_ Injectable_ Oral_ Combination_ Booster shots_ Seasonal vaccines), and Geography (North America_ LATAM_ West Europe_Central & Eastern Europe_ Northern Europe_ Southern Europe_ East Asia_ Southeast Asia_ South Asia_ Central Asia_ Oceania_ MEA)

Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 99.000 % in 2017. This stayed constant from the previous number of 99.000 % for 2016. Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 96.000 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 99.000 % in 2017 and a record low of 70.000 % in 1997. Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

According to a survey conducted in January 2021, approximately ** percent of surveyed Japanese planned to get a vaccination against the coronavirus (COVID-19). Another around **** percent stated that they decided to get a flu shot after the outbreak of COVID-19. About ** percent of respondents did not plan on getting the COVID-19 vaccine.

In 2024, the Japanese vaccine market decreased by -6.3% to $4.4B, falling for the second year in a row after three years of growth. In general, consumption, however, continues to indicate a relatively flat trend pattern. Vaccine consumption peaked at $9B in 2022; however, from 2023 to 2024, consumption remained at a lower figure.

BackgroundThe historical Japanese influenza vaccination program targeted at schoolchildren provides a unique opportunity to evaluate the indirect benefits of vaccinating high-transmitter groups to mitigate disease burden among seniors. Here we characterize the indirect mortality benefits of vaccinating schoolchildren based on data from Japan and the US. MethodsWe compared age-specific influenza-related excess mortality rates in Japanese seniors aged ≥65 years during the schoolchildren vaccination program (1978–1994) and after the program was discontinued (1995–2006). Indirect vaccine benefits were adjusted for demographic changes, socioeconomics and dominant influenza subtype; US mortality data were used as a control. ResultsWe estimate that the schoolchildren vaccination program conferred a 36% adjusted mortality reduction among Japanese seniors (95%CI: 17–51%), corresponding to ∼1,000 senior deaths averted by vaccination annually (95%CI: 400–1,800). In contrast, influenza-related mortality did not change among US seniors, despite increasing vaccine coverage in this population. ConclusionsThe Japanese schoolchildren vaccination program was associated with substantial indirect mortality benefits in seniors.

The Japan Rabies Vaccine Market size is expected to reach $78.44 Million by 2030, rising at a market growth of 4.3% CAGR during the forecast period. The rabies vaccine market in Japan has witnessed steady growth over the years. Japan has a relatively low incidence of rabies compared to other

While vaccines are pivotal in combating COVID-19, concerns about side effects and complex procedures have hindered complete vaccination. Prior studies suggest that individuals defaulted to opt-out exhibit higher COVID-19 vaccination rates compared to those in opt-in systems. However, these studies were conducted in countries with a tolerant attitude towards vaccination and default changes, targeting specific age groups, and did not address potential deterrents like the increase in cancellation rates on the day, discomfort towards changing defaults, or the possibility of the opt-out effect being a one-time occurrence. Under the hypothesis that the default nature of the COVID-19 vaccination system influences attitudes towards vaccination even in countries conservative about vaccination and default changes like in Japan, we aimed to examine the differences in the first and second dose vaccination rates, cancellation rates, and the number of complaints between the opt-in and opt-out systems for COVID-19 vaccination. An email survey was conducted in 10 cities in A Prefecture, Japan. The results showed not only higher COVID-19 vaccination rates across all comparable age groups in the opt-out group but also a notably smaller decrease in the second-dose vaccination rate compared to the opt-in group, all achieved without any complaints about the system’s introduction. Consequently, it can be inferred that the potential inhibiting factors were largely overcome. Despite some limitations, such as regional specificity, the study suggests that opt-out systems might increase COVID-19 vaccination coverage without leading to significant cancellations or complaints, presenting a promising strategy to facilitate vaccination efforts.

Japan JP: Immunization: HepB3: % of One-Year-Old Children data was reported at 99.000 % in 2019. Japan JP: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 99.000 % from Dec 2019 (Median) to 2019, with 1 observations. Japan JP: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank.WDI: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;